中国卒中杂志 ›› 2023, Vol. 18 ›› Issue (01): 1-16.DOI: 10.3969/j.issn.1673-5765.2023.01.001
• 述评 • 下一篇
熊云云, 霍晓川, 贾白雪, 濮月华, 李光硕, 王利圆, 程丝, 郝曼均, 王拥军
收稿日期:
2023-01-03
出版日期:
2023-01-20
发布日期:
2023-01-20
通讯作者:
王拥军 yongjunwang@ncrcnd.org.cn
Received:
2023-01-03
Online:
2023-01-20
Published:
2023-01-20
熊云云, 霍晓川, 贾白雪, 濮月华, 李光硕, 王利圆, 程丝, 郝曼均, 王拥军. 卒中:回眸2022[J]. 中国卒中杂志, 2023, 18(01): 1-16.
XIONG Yunyun, HUO Xiaochuan, JIA Baixue, PU Yuehua, LI Guangshuo, WANG Liyuan, CHENG Si, HAO Manjun, WANG Yongjun. Highlights in Stroke in 2022[J]. Chinese Journal of Stroke, 2023, 18(01): 1-16.
[1] SAVER J L,GOYAL M,VAN DER LUGT A,et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke:a meta-analysis[J]. JAMA,2016,316(12):1279-1288. [2] PÉREZ DE LA OSSA N,ABILLEIRA S,JOVIN T G,et al. Effect of direct transportation to thrombectomy-capable center vs local stroke center on neurological outcomes in patients with suspected large-vessel occlusion stroke in Nonurban Areas:the RACECAT randomized clinical trial[J]. JAMA,2022,327(18):1782-1794. [3] HUBERT G J,HUBERT N D,MAEGERLEIN C,et al. Association between use of a flying intervention team vs patient interhospital transfer and time to endovascular thrombectomy among patients with acute ischemic stroke in Nonurban Germany[J]. JAMA,2022,327(18):1795-1805. [4] ZACHRISON K S,SCHWAMM L H. Strategic opportunities to improve stroke systems of care[J]. JAMA,2022,327(18):1765-1767. [5] LOGALLO N,NOVOTNY V,ASSMUS J,et al. Tenecteplase versus alteplase for management of acute ischaemic stroke(NOR-TEST):a phase 3,randomised,open-label,blinded endpoint trial[J]. Lancet Neurol,2017,16(10):781-788. [6] KVISTAD C E,NÆSS H,HELLEBERG B H,et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway(NOR-TEST 2,part A):a phase 3,randomised,open-label,blinded endpoint,non-inferiority trial[J]. Lancet Neurol,2022,21(6):511-519. [7] MENON B K,BUCK B H,SINGH N,et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada(AcT):a pragmatic,multicentre,open-label,registry-linked,randomised,controlled,non-inferiority trial[J]. Lancet,2022,400(10347):161-169. [8] SANDSET E C,TSIVGOULIS G. Tenecteplase for acute ischaemic stroke[J]. Lancet,2022,400(10347):138-139. [9] YANG P,ZHANG Y,ZHANG L,et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med,2020,382(21):1981-1993. [10] ZI W Z,QIU Z M,LI F L,et al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke:the DEVT randomized clinical trial[J]. JAMA,2021,325(3):234-243. [11] SUZUKI K,MATSUMARU Y,TAKEUCHI M,et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke:the SKIP randomized clinical trial[J]. JAMA,2021,325(3):244-253. [12] LECOUFFE N E,KAPPELHOF M,TREURNIET K M,et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med,2021,385(20):1833-1844. [13] MITCHELL P J,YAN B,CHURILOV L,et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset:an open-label,blinded-endpoint,randomised non-inferiority trial[J]. Lancet,2022,400(10346):116-125. [14] FISCHER U,KAESMACHER J,STRBIAN D,et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke:an open-label,blinded-outcome,randomised non-inferiority trial[J]. Lancet,2022,400(10346):104-115. [15] KHATRI P. Intravenous thrombolysis before thrombectomy for acute ischaemic stroke[J]. Lancet,2022,400(10346):76-78. [16] GOYAL M,MENON B K,ZWAM W H,et al. Endovascular thrombectomy after large-vessel ischaemic stroke:a meta-analysis of individual patient data from five randomised trials[J]. Lancet,2016,387(10029):1723-1731. [17] ROMÁN L S,MENON B K,BLASCO J,et al. Imaging features and safety and efficacy of endovascular stroke treatment:a meta-analysis of individual patient-level data[J]. Lancet Neurol,2018,17(10):895-904. [18] DALKARA T,ARSAVA E M. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis?[J]. J Cereb Blood Flow Metab,2012,32(12):2091-2099. [19] RENU A,MILLÁN M,SAN ROMÁN L,et al. Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke:the CHOICE randomized clinical trial[J]. JAMA,2022,327(9):1-10. [20] KHATRI P. Intra-arterial thrombolysis to target occlusions in distal arteries and the microcirculation[J]. IAMA,2022,327(9):821-823. [21] SARRAJ A,GROTTA J C,PUJARA D K,et al. Triage imaging and outcome measures for large core stroke thrombectomy - a systematic review and meta-analysis[J]. J Neurointerv Surg,2020,12(12):1172-1179. [22] YOSHIMURA S,SAKAI N,YAMAGAMI H,et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med,2022,386(14):1303-1313. [23] SCHWAMM L H. In stroke,when is a good outcome good enough?[J]. N Engl J Med,2022,386(14):1359-1361. [24] MEYER L,BROOCKS G. Endovascular therapy for large acute strokes[J]. N Engl J Med,2022,386(25):2440. [25] ZI W J,QIU Z M,WU D P,et al. Assessment of endovascular treatment for acute basilar artery occlusion via a nationwide prospective registry[J]. JAMA Neurol,2020,77(5):561-573. [26] TAO C R,QURESHI A I,YIN Y M,et al. Endovascular treatment versus best medical management in acute basilar artery occlusion strokes:results from the ATTENTION multicenter registry[J]. Circulation,2022,146(1):6-17. [27] JOVIN T G,LI C H,WU L F,et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med,2022,387(15):1373-1384. [28] TAO C R,NOGUEIRA R G,ZHU Y Y,et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med,2022,387(15):1361-1372. [29] SCHONEWILLE W J. Favorable outcomes in endovascular therapy for basilar-artery occlusion[J]. N Engl J Med,2022,387(15):1428-1429. [30] STEEN W,GRAAF R A,CHALOS V,et al. Safety and efficacy of aspirin,unfractionated heparin,both,or neither during endovascular stroke treatment(MR CLEAN-MED):an open-label,multicentre,randomised controlled trial[J]. Lancet,2022,399(10329):1059-1069. [31] ALMEKHLAFI M A,COUTTS S B. Anti-thrombotics cause harm in the setting of stroke thrombectomy[J]. Lancet,2022,399(10329):1025-1026. [32] HEO J H,LEE K Y,KIM S H,et al. Immediate reocclusion following a successful thrombolysis in acute stroke:a pilot study[J]. Neurology,2003,60(10):1684-1687. [33] CANNON C P,WEINTRAUB W S,DEMOPOULOS L A,et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban[J]. N Engl J Med,2001,344(25):1879-1887. [34] QIU Z M,LI F L,SANG H F,et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke:the RESCUE BT randomized clinical trial[J]. JAMA,2022,328(6):543-553. [35] YANG P F,SONG L L,ZHANG Y W,et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke(ENCHANTED2/MT):a multicentre,open-label,blinded-endpoint,randomised controlled trial[J]. Lancet,2022,400(10363):1585-1596. [36] MISTRY E A,NGUYEN T N. Blood pressure goals after mechanical thrombectomy:a moving target[J]. Lancet,2022,400(10363):1558-1559. [37] WEIR P,MAGUIRE R,O’SULLIVAN S E,et al. A meta-analysis of remote ischaemic conditioning in experimental stroke[J]. J Cereb Blood Flow Metab,2021,41(1):3-13. [38] ENGLAND T J,HEDSTROM A,O’SULLIVAN S,et al. RECAST(remote ischemic conditioning after stroke trial):a pilot randomized placebo controlled phaseⅡtrial in acute ischemic stroke[J]. Stroke,2017,48(5):1412-1415. [39] HOU C B,LAN J,LIN Y N,et al. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis(the RICA trial):a multicentre,randomised,double-blind sham-controlled trial in China[J]. Lancet Neurol,2022,21(12):1089-1098. [40] GANESH A,SMITH E E,HILL M D. Remote ischaemic conditioning for stroke prevention[J]. Lancet Neurol,2022,21(12):1062-1063. [41] CHEN H S,CUI Y,LI X Q,et al. Effect of remote ischemic conditioning vs usual care on neurologic function in patients with acute moderate ischemic stroke:the RICAMIS randomized clinical trial[J]. JAMA,2022,328(7):627-636. [42] HESS D C,BLAUENFELDT R A,ANDERSEN G. Remote ischemic conditioning:feasible and potentially beneficial for ischemic stroke[J]. JAMA,2022,328(7):622-624. [43] DERDEYN C P,CHIMOWITZ M I,LYNN M J,et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis(SAMMPRIS):the final results of a randomised trial[J]. Lancet,2014,383(9914):333-341. [44] GAO P,WANG T,WANG D M,et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis:the CASSISS randomized clinical trial[J]. JAMA,2022,328(6):534-542. [45] BODEN W E,O’ROURKE R A,TEO K K,et al. Optimal medical therapy with or without PCI for stable coronary disease[J]. N Engl J Med,2007,356(15):1503-1516. [46] SEDLIS S P,HARTIGAN P M,TEO K K,et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease[J]. N Engl J Med,2015,373(20):1937-1946. [47] MARON D J,HOCHMAN J S,REYNOLDS H R,et al. Initial invasive or conservative strategy for stable coronary disease[J]. N Engl J Med,2020,382(15):1395-1407. [48] CHANG R W,TUCKER L Y,ROTHENBERG K A,et al. Incidence of ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA,2022,327(20):1974-1982. [49] STERPETTI A V,ARICI V,BOZZANI A. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA,2022,328(12):1255-1256. [50] HUANG K W,CHEN C W,WEI J C. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA,2022,328(12):1256. [51] SABATER-LLEAL M,HUANG J,CHASMAN D,et al. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease[J]. Circulation,2013,128(12):1310-1324. [52] MALIK R,CHAUHAN G,TRAYLOR M,et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet,2018,50(4):524-537. [53] MISHRA A,MALIK R,HACHIYA T,et al. Stroke genetics informs drug discovery and risk prediction across ancestries[J]. Nature,2022,611(7934):115-123. [54] GALLEGO-FABREGA C,MUIÑO E,CÁRCEL-MÁRQUEZ J,et al. Genome-wide studies in ischaemic stroke:are genetics only useful for finding genes?[J]. Int J Mol Sci,2022,23(12):6840. |
[1] | 周宏宇, 李子孝. 数字生物标志物:打开数智医疗应用的钥匙[J]. 中国卒中杂志, 2025, 20(4): 385-390. |
[2] | 张栗源, 刘涛, 姜勇, 李子孝, 王拥军, 杨晓萌. 基于脑影像及临床特征的机器学习模型预测缺血性卒中后心房颤动[J]. 中国卒中杂志, 2025, 20(4): 392-400. |
[3] | 程相鑫, 张烁, 杜松骏, 刘子阳, 周宏宇, 贾伟丽, 李子孝, 刘涛. 基于IMU信号的人工智能上肢多关节运动状态识别系统构建——卒中后人工智能运动功能评估与检测系统建设前导研究[J]. 中国卒中杂志, 2025, 20(4): 401-409. |
[4] | 蒲善宇, 潘岳松, 王拥军. 基于无监督学习识别吲哚布芬治疗急性中重度缺血性卒中的应答患者[J]. 中国卒中杂志, 2025, 20(4): 410-417. |
[5] | 蒋兰, 傅新民, 孙梦飞, 李怡萍. 大脑中动脉闭塞性急性缺血性卒中血管内治疗后不良预后的危险因素分析及预测模型开发[J]. 中国卒中杂志, 2025, 20(4): 418-427. |
[6] | 倪佃丽, 陈晓兵, 张广慧, 彭庆荣. 急性缺血性卒中院前延迟风险预测模型的构建及评价[J]. 中国卒中杂志, 2025, 20(4): 428-434. |
[7] | 张欣悦, 常红, 赵洁, 李佩佩, 刘梦娆, 李苏爱. 急性缺血性卒中患者运动想象训练中认知负荷与生理指标的相关性研究[J]. 中国卒中杂志, 2025, 20(4): 435-446. |
[8] | 张永庆, 李娜, 高伊丽, 秦佳文, 俞海萍, 赵婷婷. 1990—2021年中国归因于高LDL-C的卒中死亡负担变化趋势及预测分析[J]. 中国卒中杂志, 2025, 20(4): 447-456. |
[9] | 王岩, 郝怀宇, 陆强, 张蕾, 沈学延, 魏桂梅. 细胞外水分比率对急性缺血性卒中患者出院结局的影响[J]. 中国卒中杂志, 2025, 20(4): 457-461. |
[10] | 胡燕琴, 赵陶丽, 李申, 郭东兴, 赵志刚. 静脉应用银杏叶制剂治疗急性缺血性卒中有效性和安全性的meta分析[J]. 中国卒中杂志, 2025, 20(4): 462-469. |
[11] | 杨航, 高安邦, 倪莹, 马跃, 高名同. 基于cGAS-STING通路和突触融合蛋白17介导的自噬在脑缺血再灌注损伤中的作用研究进展[J]. 中国卒中杂志, 2025, 20(4): 479-485. |
[12] | 赵乾坤, 李宪东, 徐天策, 陈会生. 基于脑-肠轴探讨针灸治疗缺血性卒中机制的基础研究进展[J]. 中国卒中杂志, 2025, 20(4): 486-492. |
[13] | 池琦, 赵颖, 韩东倩, 张锶琪, 杜沛洁, 董琬玥, 徐安定, 杨振国, 孟珩. 急性缺血性卒中发病时间评估的研究进展[J]. 中国卒中杂志, 2025, 20(4): 493-499. |
[14] | 赵开杰, 孙秀亭, 袁曼, 胡婉贞, 张晓燕. 脑侧支循环评估方法的研究进展[J]. 中国卒中杂志, 2025, 20(4): 500-510. |
[15] | 郭园丽, 高任轲, 杨彩侠, 范文凤, 郭丽娜, 董小方, 吕培华, 高欢欢, 马珂珂. 急性缺血性卒中静脉溶栓意向量表的编制及信效度检验[J]. 中国卒中杂志, 2025, 20(4): 511-518. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||